Synopsis
Big Data is the process of analysing high volume, high velocity data by advanced computational methods that produce actionable knowledge. A system that suggests actions to a user is one definition of Artificial Intelligence (AI). These approaches have thrown up surprising, often counter-intuitive results, in many industries especially in on-line retail for example. Other industries have achieved a clear bottom line benefit out of Big Data (and AI). Since the last meeting in October 2019 much has happened. In the third running of this meeting the presenters will update on what is working for chemistry and what is not.
Attendees
This conference is intended to be a high level overview of the state of the art in the field for chemists interested in learning more, and for decision makers who want an update on what is going on (as opposed to an in depth conference by and for technical specialists). The previous meetings attracted a well-informed audience that was open to discussion and debate.
This event will be of interest to a wide range of scientific disciplines including project leaders, VPs and Directors of Medicinal, Agrochemical, Materials and Computational Chemistry. Technical experts in the field who want a broad update and to contribute to a vibrant meeting and discussion are also welcome.
Programme
Tuesday 6 February 2024
- 09:00
- Registration and refreshments
- 09:50
- Welcome and introduction
- 10:00
- The pros and cons of machine learning in chemistry
Prof. Charlotte Deane, Department of Statistics, University of Oxford
- 10:40
- Championing ‘Digital’ at AstraZeneca
Dr Nessa Carson, AstraZeneca plc, UK
- 11:20
- Refreshment break
- 11:40
- Bridging the gap: Integrating big data and AI into everyday practices for non-experts in drug discovery
Dr Nathan Brown, Healix Limited
- 12:20
- Gaining valuable insights from large, sparse and noisy data to guide drug discovery
Dr. Matt Segall, Optibrium Limited
- 13:00
- Lunch
- 14:00
- There’s no free lunch, but you can get a discount – applying active learning in drug discovery
Dr. Pat Walters, VP Computation at Relay Therapeutics, Boston, USA
- 14:40
- Developing an AI-first drug design platform at Isomorphic labs
Dr Miles Congreave, Dr Caroline Low, Isomorphic Labs
- 15:20
- Refreshment break
- 15:40
- How to find what you want in an expanding chemical space
Rajarshi Guha, Vertex Pharmaceuticals
- 16:30
- Using big chemistry data and AI in real life, some GSK experiences
Dr Darren Green, GlaxoSmithKline, UK
- 17:20
- Closing remarks
SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.
Sponsorship and Exhibition
For further information and prices, please email conferences@soci.org.
Venue and Contact
Fees
Early bird - ends Tuesday 9 January 2024
SCI Member - £70
Non-member - £145
Student Member - £45 |
After early bird
SCI Member - £120
Non-member - £195
Student Member - £85 |
All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
Booking terms and conditions
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Organising committee
- Dr Alexander G. Dossetter, MedChemica Limited
- Dr Martin Lowe, ExScientia
- Dr Pascal Savy, Isomorphic Labs
- Dr Samuel Coe, Evotec